The nation of Zimbabwe has rejected a major US health deal valued at 367 million US dollars (272 million pounds) spanning five years due to the United States' request for confidential information.
The decision was revealed following a government memo from December was leaked, which showed President Emmerson Mnangagwa deemed the agreement was "unbalanced".
A government representative has since stated that the United States was demanding access to genetic material for scientific study and profit while was not willing to share the resulting advantages from any future medical innovations.
"We are forced to start the challenging and unfortunate task of scaling back our support in Zimbabwe," stated US ambassador to Zimbabwe Pamela Tremont publicly.
Her embassy said the United States had furnished over $1.9bn for health programmes to Zimbabwe over the last twenty years.
A physicians' group in Zimbabwe has appealed for more negotiations to secure a agreement suitable to both sides so the nation's critical HIV programme can continue.
Wider Background
Zimbabwe's decision comes after a comparable situation in neighbouring Kenya, where a high court suspended a similar deal with the US following concerns were filed about the safety of citizens' medical information.
Since returning to office last year, US President Donald Trump has slashed foreign aid and shut down the key foreign aid agency.
USAID had administered assistance for the US government, but Trump claimed its expenditure was "inefficient" and his government was pursuing direct bilateral deals to enhance openness and responsibility.
Based on reports, Sixteen African countries have so far signed these new health pacts, constituting more than $18.3bn in new funding.
Details of the Declined Deal
The money for Zimbabwe was intended to gone towards "combating HIV/Aids, TB, malaria, healthcare for mothers and children, and preparing for epidemics".
"We believe this cooperation might have yielded immense advantages for Zimbabwean communities, particularly the 1.2 million men, women and children presently receiving antiretroviral therapy through US-supported initiatives," the Ambassador commented.
However, official spokesman Nick Mangwana argued the arrangement was "asymmetrical".
"Zimbabwe was being asked to share its genetic material and health information over an extended period, without any corresponding assurance of benefiting from any scientific breakthroughs – like new medicines or tests – that could be developed from that provided information," he stated.
"Put simply, our nation would provide the basic resources for medical research without any certainty that the end products would be accessible to our citizens if a new health crisis emerge."
National Interest and International Frameworks
He also said that the American exit from the global health body and its push of bilateral health agreements were upending frameworks already established through the global organization.
The spokesperson gave as an example its Pandemic Benefit-Sharing framework created to deal with future global health emergencies.
"This system is designed to ensure that when a country provides its samples, the benefits – including vaccines and treatments – are shared equitably, not commercialised exclusively by those with the capability to create them."
The government's concerns over the US deal "should not be misconstrued as opposition to America," Mangwana stressed.
"We are open to continued dialogue with our American counterparts on how future collaboration could be arranged in a manner that honours the independence and dignity of both nations."
Health Experts Response
The Zimbabwe College of Public Health Physicians (ZCPHP) said it acknowledged the official position, but recommended that talks should continue considering much of the country's Aids initiatives relied on foreign aid.
"If technical issues exist, including those involving data governance or implementation frameworks, these can often be resolved through technical clarification and negotiated safeguards," the group commented.
The halted deal highlights the complex tensions between accepting crucial foreign assistance and protecting a country's data in an increasingly data-driven world.